The primary objective of the phase II study is to evaluate the efficacy on negative symptoms of two doses of Lu AF11167 versus placebo as monotherapy in patients with schizophrenia and persistent prominent negative symptoms. The secondary objective will be to evaluate the efficacy of Lu AF11167 on patients’ functioning as well as the safety and tolerability of the compound. This 3-arm study will randomize a total of 240 patients (80 patients per arm) from various European countries.
6 Likes
Any progress is good.
1 Like
I wonder will this drug be strong enough to controll my positives i suffer from negatives but i dont id rather live with them then positives.
I wonder if anyone on here has any experience with pde10 inhibitors
nope just pde5 
1 Like
Probably not, I believe it’s a new mechanism of action.
Im sure Lundbecks med is more selective but unless I read the wiki wrong Papaverine and a few other things inhibit pde10
1 Like
I’m European. Do you know if I can join the study?
They might add other sites later - the press release implies.
Interesting, I recognized a few other PDE types, like vinpocetine and rolfumilast.
Seems Takeda is working on a PDE10 inhibitor too. From what I have read it seems like they will have to be taken as monotherapy, that taking them with D2 blockers would make them not work.
Pfizer had one fail for Huntington’s disease too I think.